

June 16, 2020

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

SECURITY ID : BAYERCROP SECURITY CODE : 506285

Dear Sir / Madam,

Sub.: Disclosures of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions for the half year ended March 31, 2020.

Kindly take the said information on your records.

Thanking you.

Yours faithfully,

for Bayer CropScience Limited

Nikunjkumar Savaliya Company Secretary & Company Secretary

Encl. : As above

Bayer CropScience Ltd. CIN: L24210MH1958PLC011173

Registered and Corporate Office: Bayer House Central Avenue Hiranandani Estate Thane (West) – 400 607 Maharashtra, India

Tel: +91 22 2531 1234 Fax: +91 22 2545 5063 www.bayer.in www.cropscience.bayer.com



BAYER CROPSCIENCE LIMITED

Disclosure of Related Party Transactions for the half year ended March 31, 2020 (All amounts in ` Millions, unless otherwise stated)

Sr. No.	Name of the related party	Country of incorporation	<u>% Equity interest</u> As at 31.03.2020
i)	Ultimate Holding Company:		31.03.2020
	Bayer AG	Germany	8%
ii)	•		
	Bayer (China) Limited, China		
	Bayer (Proprietary) Limited, South Africa		
	Bayer (South East Asia) Pte. Ltd., Singapore		
	Bayer BioScience Private Limited, India		
	Bayer Business and Technology Services LLC, U.S.A.		
	Bayer Business Services GmbH, Germany		
	Bayer Business Services Philippines Inc., Philippines		
	Bayer CropScience (China) Co. Ltd., China		
	Bayer CropScience AG, Germany		
	Bayer CropScience Limited, Bangladesh		
	Bayer CropScience LP, U.S.A.		
	Bayer CropScience Ltd, Korea		
	Bayer CropScience Inc., Philippines		
	Bayer CropScience Schweiz AG, Switzerland		
	Bayer Direct Services GmbH, Germany Bayer HealthCare Pharmaceuticals Inc., U.S.A.		
	Bayer Holding Ltd., Japan		
	Bayer Intellectual Property GmbH, Germany		
	Bayer Pakistan (Private) Limited, Pakistan		
	Bayer Pharmaceuticals Private Limited, India		
	Bayer Philippines Inc., Philippines		
	Bayer S.A., Chile		
	Bayer S.A.S., France		
	Bayer Thai Company Limited, Thailand		
	Bayer Vapi Private Limited, India (the Enterprise in respect of which, the Company	is an Associate)	
	Bayer Vietnam Ltd., Vietnam Bayer Zydus Pharma Private Limited, India		
	Monsanto Company, U.S.A.		
	Monsanto Holdings Private Limited, India		
	Monsanto India Investments Private Limited, India		
	Monsanto Nigeria, Nigeria		
	Monsanto Thailand Ltd, Thailand		
	PT. Bayer Indonesia, Indonesia		
	** The list of parties above have been limited to entities with whom transactions h	ave taken place during the c	urrent or previous year or
	balances are outstanding as at the year end.		r · · · · / · · •·

A. The transactions with related parties:

A me duibactoris man related parties		
	Party referred to in (i) above	Parties referred to in (ii) above
	01.10.2019 to 31.03.2020	01.10.2019 to 31.03.2020
Sale of goods		
Bayer AG	377	-
Bayer BioScience Private Limited	-	8
Bayer Vapi Private Limited	-	_*
Others	-	250
Recoveries made		
Baver AG	38	-
Bayer BioScience Private Limited	-	49
Bayer Vapi Private Limited	-	132
Others	-	207
Rental Income		
Bayer BioScience Private Limited	-	2
Bayer Vapi Private Limited	-	3
Others	-	41
001010		11
Purchase of Goods		
Bayer AG	3,434	-
Bayer BioScience Private Limited [#]	-	-154
Bayer Vapi Private Limited	-	55
Monsanto Company	-	450
# The amount is disclosed on gross basis, against which revenue is acting as an agent in substance.	recognised at margin (sales less material cos	t) since the Company is



BAYER CROPSCIENCE LIMITED

Monsanto Company

Others

Disclosure of Related Party Transactions for the half year ended March 31, 2020 (All amounts in ` Millions, unless otherwise stated)

Parties referred to in Party referred to in (i) above (ii) above 01.10.2019 to 01.10.2019 to 31.03.2020 31.03.2020 Professional/ Support Charges incurred Bayer AG 2 Bayer Vapi Private Limited 11 Monsanto Company 62 Others 444 Rent Expense Bayer BioScience Private Limited Bayer Vapi Private Limited 7 _* Monsanto Company _* Others 1 Payment of Lease Liabilities Bayer BioScience Private Limited 5 Bayer Vapi Private Limited 1 -* Others Royalty Expense Bayer CropScience AG Monsanto Company 3 85 Sale of Fixed Assets Bayer Vapi Private Limited _* Others 2 Purchase of License of Duty Credit Scrips Bayer BioScience Private Limited Bayer Vapi Private Limited -18 trf to corr Co code 122 Purchase of Fixed Assets (including Capital work-in-progress) Others 2 Recoupment of losses towards overdue trade receivables Bayer BioScience Private Limited 5 Employee related liability paid/ payable on transfer of employees Others 9 Employee related liability taken over on transfer of employees Bayer BioScience Private Limited 35 2 27 Bayer Vapi Private Limited Others *Amount is below rounding off norm adopted by the Company. B. Outstanding balances of related parties: As at 31.03.2020 Party referred to in (i) above Outstanding Receivables 93 1,891 Outstanding Payables Parties referred to in (ii) above Outstanding Receivables Bayer BioScience Private Limited 22 Monsanto Company Others 193 Outstanding Payables Bayer BioScience Private Limited 360 Bayer Vapi Private Limited

627

285



BAYER CROPSCIENCE LIMITED

Disclosure of Related Party Transactions for the half year ended March 31, 2020 (All amounts in ` Millions, unless otherwise stated)

iii) Employee Benefits Plans where significant influence exists

Bayer CropScience Limited Employees Group Gratuity-cum-Life Assurance Scheme Bayer CropScience Limited Managerial Employees Superannuation Scheme

The transactions with entries where significant influence exis	ts of (iii) above and outstanding balances: 01.10.2019 to
	31.03.2020
Contributions during the year Bayer CropScience Limited Managerial Employees Superannuation S	icheme13
) Key management personnel:	
Name	Designation
- Mr. Pankaj Patel	Chairman
- Mr. Duraiswami Narain	Vice Chairman & Managing Director and CEO
- Mr. Rolf Hoffmann	Executive Director & CFO
- Ms. Ketaki Bhagwati	Non-executive Director
- Mr. Sekhar Natarajan	Non-executive Director (from October 1, 2019)
	01.10.2019 to
	31.03.2020
Remuneration to key management personnel	
Short term employee benefits	109
Other long-term employee benefits	-1
	108
Divertexal Citting Free	.*
Directors' Sitting Fees	-*
Commission to Non-Executive Directors	3
) Terms and conditions	

There have been no guarantees provided or received for any related party receivables or payables. Outstanding balances at the year end are unsecured and interest free, and settlement occurs in cash. The Company has not recorded any impairment of receivables relating to amounts owed by related parties for the year ended March 31, 2020 and March 31, 2019.

RESTRICTED